Response to a Novel Multitargeted Tyrosine Kinase Inhibitor Pazopanib in Metastatic Merkel Cell Carcinoma
Authors:
- 10 September 2009
- journal article
- case report
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (26) , e97-e100
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Silent mutations in KIT and PDGFRA and coexpression of receptors with SCF and PDGFA in Merkel cell carcinoma: implications for tyrosine kinase-based tumorigenesisLaboratory Investigation, 2008
- A Comprehensive Review of the Treatment of Merkel Cell CarcinomaAmerican Journal of Clinical Oncology, 2007
- Merkel cell carcinoma adjuvant therapy: Current data support radiation but not chemotherapyJournal of the American Academy of Dermatology, 2007
- Expression profiles associated with aggressive behavior in Merkel cell carcinomaLaboratory Investigation, 2007
- Pazopanib: A novel multitargeted tyrosine kinase inhibitorCurrent Oncology Reports, 2007
- Absence of Classical MAP Kinase Pathway Signalling in Merkel Cell CarcinomaJournal of Investigative Dermatology, 2006
- The promise of molecular targeted therapies: Protein kinase inhibitors in the treatment of cutaneous malignanciesJournal of the American Academy of Dermatology, 2005
- Merkel Cell Carcinoma: Prognosis and Treatment of Patients From a Single InstitutionJournal of Clinical Oncology, 2005
- C-KIT Expression in Primary and Metastatic Merkel Cell CarcinomaThe American Journal of Dermatopathology, 2004
- Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinomaCancer, 1999